

## **Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT)**

### **Additional data regarding UK specific mycotoxin biomonitoring data and mode of action toxicity mechanisms for single mycotoxins**

#### **Background**

1. A preliminary scoping paper regarding the potential risks from aggregated dietary exposure to mycotoxins (TOX/2020/34)<sup>1</sup> was presented to the COT in July 2020. Following discussions, the Committee requested for the Secretariat to perform a literature search on the availability of biomonitoring data for multiple mycotoxin exposures specific to the United Kingdom (UK) population. The collated data is presented in Annex A.
2. The Secretariat was further requested to collate the toxic mode of action (MoA) for the reviewed single mycotoxins as listed in Annex B of TOX/2020/34<sup>2</sup> this includes; aflatoxins, ochratoxin A, patulin, type A trichothecenes (T-2 and HT-2 toxins), 4,15-diacetoxyscirpenol, deoxynivalenol and its acetylated metabolites (3-acetyldeoxynivalenol and 15-acetyldeoxynivalenol), nivalenol, fusarenon-X, zearalenone, fumonisin B<sub>1</sub> and B<sub>2</sub> subtypes, citrinin, ergot alkaloids, cyclopiazonic acid, moniliformin, neosolaniol and sterigmatocystin.
3. Obtaining the MoA will aid Committee members to perform a higher tier grouping exercise for the above mycotoxins in comparison to grouping based on toxic endpoints. This information is tabulated in Annex B.

#### **Questions on which the views of the Committee are sought:**

4. Members are invited to review the data in the Annexes and consider the following questions and to raise any other matters that arise from the newly submitted data:
  - i). Do Members have any comments on the additional data gathered on biomonitoring (Annex A)?
  - ii). Do Members have any comments on the additional data gathered on MoA (Annex B)?
  - iii). On the basis of the collated MoA data, is the Committee able to make decisions on the potential grouping of mycotoxins?

---

<sup>1</sup> TOX/2020/34 available on the [COT website](#).

<sup>2</sup> TOX/2020/34 Annex B available on the [COT website](#).

This is a background paper for discussion. It does not reflect the views of the Committee and should not be cited.

- iv). Which data gap(s) do the Committee consider to be more important, so that a risk assessment may be performed?
- v). What future research would the Committee recommend?
- vi). Does the Committee have any other comments?

**Secretariat**  
**September 2020**